Pibrentasvir
MAVYRET
Pronunciation: pi-BRENT-as-veer (MAV-i-ret)
What it isHCV NS5A inhibitor, given with glecaprevir; chronic hepatitis C.
Why this onePangenotypic with a high barrier to resistance, allowing the short combination course.
What limits itHepatitis B reactivation, so B status must be known. It inhibits P-gp, BCRP and OATP1B; statin doses must fall.
FDA-approved for
- chronic hepatitis C (2017)
⚠ BOXED WARNING
- Hepatitis B virus reactivation in patients coinfected with HCV and HBV
Principal riskHepatitis B reactivation; statin doses must fall
Classes and tags
Clinical profile
Legacy pregnancy categoryN/A (post-2015 labeling)
Defining liabilityCombination-regimen HBV reactivation and hepatic decompensation risk
Open Pibrentasvir in the interactive console ↗
Memory aids: interaction avatars
